A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
They include MET-233i, an injectable amylin analog that is Metsera’s answer to the sector’s search for a once-monthly dosing ...
MET-233i and Metsera’s other next-generation NuSH analog peptides are also engineered with Metsera’s HALO™ lipidation platform. Oral GLP-1 RA peptide program clinical trial initiated Metsera has ...
Metsera also has clinical trials underway for an injectable amylin analog called MET-233i and an oral GLP-1 peptide called ...
While semaglutide works by hampering appetite and controlling blood sugar levels by mimicking the GLP-1 hormone, cagrilintide ...
The bi-weekly formulation of GLP-1 has the potential to enhance patient adherence ... About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & ...
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of ...
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback